The Journal
Evidence-led reading on longevity, GLP-1 medicines, regenerative injectables and the trends that will define 2027.
Immortality is not on the horizon. But for the first time, therapies designed to slow or reverse parts of ageing are being tested in people. Here is what is real, what is hype and what it means for aesthetics.
In 2026 a therapy built on David Sinclair's epigenetic reprogramming research was given to people for the first time, in an attempt to restore sight lost to glaucoma and optic nerve stroke. Here is what the early data shows.
Oral GLP-1 tablets, higher-dose injections and millions of new patients. How the GLP-1 revolution moved on in 2026, and why it is reshaping aesthetic practice.
Regeneration over correction, GLP-1 pathways, licensing, longevity menus and AI consultations. The ten trends that will define aesthetic medicine in 2027.
Age reversal entered human trials, GLP-1s went oral, regeneration became mainstream and regulation took shape. Why 2026 will be remembered as the year aesthetics changed permanently.
What polynucleotides and PDRN are, how they differ, where they are used and how to choose between leading brands. A clear guide to aesthetics' most talked-about regenerative injectable.
Exosomes are the most hyped ingredient in regenerative aesthetics. What they are, what the evidence shows, how they are used and what UK practitioners need to know.
Skin boosters and dermal fillers are both hyaluronic acid injectables, but they do very different jobs. How they differ, when to use each and how to combine them.
Biostimulators prompt the body to build its own collagen. A guide to PLLA, CaHA, PCL and hybrid injectables, how they differ and where they fit in modern treatment plans.
NAD+ is the molecule at the centre of the longevity conversation. What it does, why levels fall with age, what the human evidence says and how clinics should talk about it.
